<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="0e9fe0fb-2ada-4e64-a74e-eb9d6fea5853"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use DORYX MPC safely and effectively. See full prescribing information for DORYX MPC<br/>
      <br/> DORYX MPC (doxycycline hyclate delayed-release tablets), for oral use.<br/>Initial U.S. Approval: 1967</title>
   <effectiveTime value="20250403"/>
   <setId root="f9277bb8-982d-444d-9325-35d5c53a2d35"/>
   <versionNumber value="14"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="867220261" root="1.3.6.1.4.1.519.1"/>
            <name>Mayne Pharma Commercial LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="756003745" root="1.3.6.1.4.1.519.1"/>
                        <name>Mayne Pharma International Pty Ltd</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-560" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-559" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-560" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-559" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-560" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-559" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-560" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-559" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="118812386" root="1.3.6.1.4.1.519.1"/>
                        <name>Catalent Greenville, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-560" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-559" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-560" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-559" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-560" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-559" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="b38a3397-fc88-44ef-be2e-8babd565783c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250301"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="51862-560" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>DORYX MPC</name>
                        <formCode code="C42905" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, DELAYED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>doxycycline hyclate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="60" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="19XTS3T51U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Doxycycline Hyclate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="334895S862" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Doxycycline Anhydrous</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Lactose Monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Microcrystalline Cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Lauryl Sulfate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Talc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Anhydrous Lactose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Starch, Corn</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (120 .MU.M)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium Stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="120" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="51862-560-12" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230102"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="6" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="51862-560-00" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230102"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="51862-560-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240513"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA050795" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230102"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>containing yellow pellets</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="12" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">D;6</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="51862-559" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>DORYX MPC</name>
                        <formCode code="C42905" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, DELAYED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Doxycycline Hyclate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="120" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="19XTS3T51U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Doxycycline Hyclate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="334895S862" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Doxycycline Anhydrous</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Lactose Monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Microcrystalline Cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Lauryl Sulfate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Talc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Anhydrous Lactose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Starch, Corn</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (120 .MU.M)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium Stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="51862-559-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20171229"/>
                                    <high value="20240630"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA050795" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20160701"/>
                              <high value="20240630"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>containing yellow pellets</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="15" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">D;C</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="504d525a-29b6-4ce0-b872-42ae51e351d6"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="90%" align="left" valign="top"/>
                           <col width="10%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Warnings and Precautions, Severe Skin Reactions (<linkHtml href="#S5.5">5.5</linkHtml>)</td>
                                 <td>03/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="69e4818d-43ca-4bde-aeff-da816d586548"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1	INDICATIONS AND USAGE</title>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>DORYX MPC is a tetracycline class drug indicated for:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Rickettsial Infections (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                           <item>Sexually Transmitted Infections (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                           <item>Respiratory Tract Infections(<linkHtml href="#S1.3">1.3</linkHtml>)</item>
                           <item>Specific Bacterial Infections (<linkHtml href="#S1.4">1.4</linkHtml>)</item>
                           <item>Ophthalmic Infections (<linkHtml href="#S1.5">1.5</linkHtml>)</item>
                           <item>Anthrax, Including Inhalational Anthrax (Post-Exposure) (<linkHtml href="#S1.6">1.6</linkHtml>)</item>
                           <item>Alternative Treatment for Selected Infections when Penicillin is Contraindicated (<linkHtml href="#S1.7">1.7</linkHtml>)</item>
                           <item>Adjunctive Therapy in Acute Intestinal Amebiasis and Severe Acne (<linkHtml href="#S1.8">1.8</linkHtml>)</item>
                           <item>Prophylaxis of Malaria (<linkHtml href="#S1.9">1.9</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Usage</content>
                        </paragraph>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate and other antibacterial drugs, DORYX MPC Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (<linkHtml href="#S1.10">1.10</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="58793b0f-24d1-4286-b073-f5c63be455e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1	Rickettsial Infections</title>
                     <text>
                        <paragraph>DORYX MPC is indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by <content styleCode="italics">Rickettsiae</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="5fb63921-4e1a-4d2f-a1e1-2c677c28bba4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2	Sexually Transmitted Infections</title>
                     <text>
                        <paragraph>DORYX MPC is indicated for treatment of the following sexually transmitted infections:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Uncomplicated urethral, endocervical or rectal infections in adults caused by <content styleCode="italics">Chlamydia trachomatis.</content>
                           </item>
                           <item>Nongonococcal urethritis caused by <content styleCode="italics">Ureaplasma urealyticum</content>.</item>
                           <item>Lymphogranuloma venereum caused by <content styleCode="italics">Chlamydia trachomatis</content>.</item>
                           <item>Granuloma inguinale caused by <content styleCode="italics">Klebsiella granulomatis</content>.</item>
                           <item>Uncomplicated gonorrhea caused by <content styleCode="italics">Neisseria gonorrhoeae</content>.</item>
                           <item>Chancroid caused by <content styleCode="italics">Haemophilus ducreyi</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.3">
                     <id root="a4edb93e-9223-4fdb-9d09-36e9af6770b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3	Respiratory Tract Infections</title>
                     <text>
                        <paragraph>DORYX MPC is indicated for treatment of the following respiratory tract infections:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Respiratory tract infections caused by <content styleCode="italics">Mycoplasma pneumoniae</content>.</item>
                           <item>Psittacosis (ornithosis) caused by <content styleCode="italics">Chlamydophila psittaci</content>.</item>
                           <item>Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.</item>
                           <item>Doxycycline is indicated for treatment of infections caused by the following microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug: <list>
                                 <item>
                                    <caption>–</caption> Respiratory tract infections caused by <content styleCode="italics">Haemophilus influenzae</content>.</item>
                                 <item>
                                    <caption>–</caption> Respiratory tract infections caused by <content styleCode="italics">Klebsiella</content> species.</item>
                                 <item>
                                    <caption>–</caption> Upper respiratory infections caused by <content styleCode="italics">Streptococcus pneumoniae</content>.</item>
                              </list>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.4">
                     <id root="55df07bb-61ec-4c7c-8f0a-034234e7d6b2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4	Specific Bacterial Infections</title>
                     <text>
                        <paragraph>DORYX MPC is indicated for treatment of the following specific bacterial infections:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Relapsing fever due to <content styleCode="italics">Borrelia recurrentis</content>.</item>
                           <item>Plague due to <content styleCode="italics">Yersinia pestis</content>.</item>
                           <item>Tularemia due to <content styleCode="italics">Francisella tularensis</content>.</item>
                           <item>Cholera caused by <content styleCode="italics">Vibrio cholerae</content>.</item>
                           <item>Campylobacter fetus infections caused by <content styleCode="italics">Campylobacter fetus</content>.</item>
                           <item>Brucellosis due to <content styleCode="italics">Brucella</content> species (in conjunction with streptomycin).</item>
                           <item>Bartonellosis due to <content styleCode="italics">Bartonella bacilliformis</content>.</item>
                        </list>
                        <paragraph>Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.</paragraph>
                        <paragraph>DORYX MPC is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Escherichia coli</item>
                           <item>Enterobacter aerogenes</item>
                           <item>Shigella species</item>
                           <item>Acinetobacter species</item>
                           <item>Urinary tract infections caused by Klebsiella species.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.5">
                     <id root="127d4cf0-26ce-4f87-b703-719575a3bda1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.5	Ophthalmic Infections</title>
                     <text>
                        <paragraph>DORYX MPC is indicated for treatment of the following ophthalmic infections:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Trachoma caused by <content styleCode="italics">Chlamydia trachomatis</content>, although the infectious agent is not always eliminated as judged by immunofluorescence.</item>
                           <item>Inclusion conjunctivitis caused by <content styleCode="italics">Chlamydia trachomatis</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.6">
                     <id root="5dbbb536-9d2c-4ea8-91f0-2fecda696b74"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.6	Anthrax Including Inhalational Anthrax (Post-Exposure)</title>
                     <text>
                        <paragraph>DORYX MPC is indicated for treatment of Anthrax due to <content styleCode="italics">Bacillus anthracis</content>, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized <content styleCode="italics">Bacillus anthracis</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.7">
                     <id root="3ee9f5e7-38b5-4f15-b661-3e06dbbe7816"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.7	Alternative Treatment for Selected Infections when Penicillin is Contraindicated</title>
                     <text>
                        <paragraph>DORYX MPC is indicated as an alternative treatment for the following selected infections when penicillin is contraindicated:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Syphilis caused by <content styleCode="italics">Treponema pallidum</content>.</item>
                           <item>Yaws caused by <content styleCode="italics">Treponema pallidum</content> subspecies <content styleCode="italics">pertenue</content>.</item>
                           <item>Listeriosis due to <content styleCode="italics">Listeria monocytogenes</content>.</item>
                           <item>Vincent's infection caused by <content styleCode="italics">Fusobacterium fusiforme.</content>
                           </item>
                           <item>Actinomycosis caused by <content styleCode="italics">Actinomyces israelii</content>.</item>
                           <item>Infections caused by <content styleCode="italics">Clostridium</content> species.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.8">
                     <id root="db94a849-e305-4778-be27-f9d36f9898f1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.8	Adjunctive Therapy for Acute Intestinal Amebiasis and Severe Acne</title>
                     <text>
                        <paragraph>In acute intestinal amebiasis, DORYX MPC may be a useful adjunct to amebicides.</paragraph>
                        <paragraph>In severe acne, DORYX MPC may be useful adjunctive therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.9">
                     <id root="a8e3fe4c-fdbe-4181-8c1a-101e91e6b0a0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.9	Prophylaxis of Malaria</title>
                     <text>
                        <paragraph>DORYX MPC is indicated for the prophylaxis of malaria due to <content styleCode="italics">Plasmodium falciparum</content> in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains [<content styleCode="italics">see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.10">
                     <id root="edaeeba4-b6a1-410e-8174-84db9b9182a9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.10	Usage</title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORYX MPC and other antibacterial drugs, DORYX MPC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="e92ef644-f43b-445c-ae53-69f2cf9144fc"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2	DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Important Dosage and Administration Instructions:</content>
                              <list listType="unordered" styleCode="Circle">
                                 <item>DORYX MPC is not substitutable on a mg per mg basis with other oral doxycyclines. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                                 <item>Do not chew or crush tablets. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                              </list>
                           </item>
                           <item>
                              <content styleCode="underline">Dosage in Adult Patients</content>
                              <list listType="unordered" styleCode="Circle">
                                 <item>The usual dosage of DORYX MPC is 240 mg on the first day of treatment (administered 120 mg every 12 hours) followed by a maintenance dose of 120 mg daily. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                                 <item>In the management of more severe infections (particularly chronic infections of the urinary tract), 120 mg every 12 hours is recommended. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                              </list>
                           </item>
                           <item>
                              <content styleCode="underline">Dosage in Pediatric Patients</content>
                              <list>
                                 <item>For all pediatric patients weighing less than 45 kg with severe or life threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dosage of DORYX MPC is 2.6 mg per kg of body weight administered every 12 hours. Pediatric patients weighing 45 kg or more should receive the adult dose. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                                 <item>For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule of DORYX MPC is 5.3 mg per kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.6 mg per kg of body weight (given as a single daily dose or divided into twice daily doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                              </list>
                           </item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>See Full Prescribing Information for additional indication specific dosage information and important administration instructions for DORYX MPC. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.5">2.5</linkHtml>, <linkHtml href="#S2.6">2.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="5b3d355e-d5b0-4a01-ad37-235a2e0dd6b7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Important Dosage and Administration Instructions</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>DORYX MPC is not substitutable on a mg per mg basis with other oral doxycyclines. To avoid prescribing errors, do not substitute DORYX MPC for other oral doxycyclines on a mg per mg basis because of differing bioavailability.</item>
                           <item>Do not chew or crush tablets.</item>
                           <item>The recommended dosage, frequency of administration and weight-based dosage recommendations of DORYX MPC differ from that of the other tetracyclines [<content styleCode="italics">see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S2.4">2.4)</linkHtml>
                              </content>]<content styleCode="italics">.</content>  Exceeding the recommended dosage may result in an increased incidence of adverse reactions.</item>
                           <item>Administer DORYX MPC with an adequate amount of fluid to wash down the drug and reduce the risk of esophageal irritation and ulceration [<content styleCode="italics">see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>
                              </content>].</item>
                           <item>If gastric irritation occurs, DORYX MPC may be given with food or milk <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="eeb61cd7-6934-49f3-902b-2a5042dc54bc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Switching from DORYX to DORYX MPC</title>
                     <text>
                        <paragraph>When switching from DORYX to DORYX MPC<content styleCode="italics">:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>A 60 mg dose of DORYX MPC will replace a 50 mg dose of DORYX</item>
                           <item>A 120 mg dose of DORYX MPC will replace a 100 mg dose of DORYX</item>
                        </list>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="8378f9d8-aef0-4427-9d64-f50197eef723"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Dosage in Adult Patients</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The usual dosage of DORYX MPC is 240 mg on the first day of treatment (administered 120 mg every 12 hours) followed by a maintenance dose of 120 mg daily.  The maintenance dose may be administered as a single dose or as 60 mg every 12 hours.</item>
                           <item>In the management of more severe infections (particularly chronic infections of the urinary tract), 120 mg every 12 hours is recommended.</item>
                           <item>For certain selected specific indications, the recommended duration or dosage and duration of DORYX MPC in adult patients are as follows: <list listType="ordered" styleCode="Arabic">
                                 <item>Streptococcal infections, therapy should be continued for 10 days.</item>
                                 <item>Uncomplicated urethral, endocervical, or rectal infection caused by <content styleCode="italics">C. trachomatis</content>: 120 mg, by mouth, twice-a-day for 7 days.</item>
                                 <item>Uncomplicated gonococcal infections in adults (except anorectal infections in men):  120 mg, by mouth, twice-a-day for 7 days.  As an alternate single visit dose, administer 360 mg followed in one hour by a second 360 mg dose.</item>
                                 <item>Nongonococcal urethritis (NGU) caused by <content styleCode="italics">C. trachomatis</content> and <content styleCode="italics">U. urealyticum</content>:  120 mg, by mouth, twice-a-day for 7 days.</item>
                                 <item>Syphilis – early:  Patients who are allergic to penicillin should be treated with doxycycline 120 mg, by mouth, twice-a-day for 2 weeks.</item>
                                 <item>Syphilis of more than one year's duration:  Patients who are allergic to penicillin should be treated with doxycycline 120 mg, by mouth, twice-a-day for 4 weeks.</item>
                                 <item>Acute epididymo-orchitis caused by <content styleCode="italics">N. gonorrhoeae</content>:  120 mg, by mouth, twice-a-day for at least 10 days.</item>
                                 <item>Acute epididymo-orchitis caused by <content styleCode="italics">C. trachomatis</content>:  120 mg, by mouth, twice-a-day for at least 10 days</item>
                              </list>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="88136ffc-f3cd-459a-914b-f02f0382cf67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Dosage in Pediatric Patients</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>For all pediatric patients weighing less than 45 kg with severe or life threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dosage of DORYX MPC is 2.6 mg per kg of body weight administered every 12 hours. Pediatric patients weighing 45 kg or more should receive the adult dose <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                           <item>For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule of DORYX MPC is 5.3 mg per kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.6 mg per kg of body weight (given as a single daily dose or divided into twice daily doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="900d0cc1-1c0b-44d7-ad62-a1b4720f07df"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5	Dosage for Prophylaxis of Malaria</title>
                     <text>
                        <paragraph>For adults, the recommended dose of DORYX MPC is 120 mg daily. </paragraph>
                        <paragraph>For pediatric patients 8 years of age and older, the recommended dosage of DORYX MPC is 2.4 mg per kg of body weight administered once daily. Pediatric patients weighing 45 kg or more should receive the adult dose<content styleCode="bold">.</content>
                        </paragraph>
                        <paragraph>Prophylaxis should begin 1 or 2 days before travel to the malarious area. Prophylaxis should be continued daily during travel in the malarious area and for 4 weeks after the traveler leaves the malarious area.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="5f876b86-8b33-4035-8cff-5bee8157e3e0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6	Dosage for Inhalational Anthrax (Post-Exposure)</title>
                     <text>
                        <paragraph>For adults, the recommended dosage is 120 mg, of DORYX MPC, by mouth, twice-a-day for 60 days. </paragraph>
                        <paragraph>For pediatric patients weighing less than 45 kg, the recommended dosage of DORYX MPC is 2.6 mg per kg of body weight, by mouth, twice-a-day for 60 days. Pediatric patients weighing 45 kg or more should receive the adult dose.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="85b294d7-9447-42ca-b176-ad8e669f913a"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3	DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>DORYX MPC (doxycycline hyclate delayed-release tablets), 60 mg are white, oval tablets containing yellow pellets and debossed with "D6" on one face and plain on the other. Each tablet contains doxycycline 60 mg (equivalent to doxycycline hyclate 69.4 mg).</paragraph>
               </text>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>DORYX MPC Delayed-Release Tablets 60 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="496dddab-c932-4535-8f7e-d732c0b67f6e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4	CONTRAINDICATIONS</title>
               <text>
                  <paragraph>DORYX MPC is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.</paragraph>
               </text>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Doxycycline is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="4f8e53f6-9e9f-4378-9879-531d6dd8b5d0"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5	WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The use of drugs of the tetracycline-class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Clostridioides difficile</content>-Associated Diarrhea. Evaluate patients if diarrhea occurs. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Limit sun exposure. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Overgrowth of non-susceptible organisms, including fungi, may occur. If such infections occur, discontinue use and institute appropriate therapy. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="41125dcf-779a-446b-a539-d319af258b14"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Tooth Development</title>
                     <text>
                        <paragraph>The use of drugs of the tetracycline-class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use DORYX MPC in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="b40b3fbc-4af6-4a6e-9944-b84aa48e7bfc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 <content styleCode="italics">Clostridioides </content>difficile Associated Diarrhea</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile</content> associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including DORYX MPC Tablets, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C<content styleCode="bold">.</content> difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="287b0a46-efed-4c2e-97d2-59ec67410998"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Photosensitivity</title>
                     <text>
                        <paragraph>Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="b01e189a-9a7a-4e3f-8a4d-fe32cbb41d65"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Potential for Microbial Overgrowth</title>
                     <text>
                        <paragraph>DORYX MPC may result in overgrowth of non-susceptible organisms, including fungi. If such infections occur, discontinue use and institute appropriate therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="787b8e8b-2114-430d-9bc5-bf21b12162a7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5  	Severe Skin Reactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Severe skin reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in patients receiving doxycycline. Fixed drug eruptions have occurred with doxycycline and have been associated with worsening severity upon subsequent administrations, including generalized bullous fixed drug eruption [See <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]. If severe skin reactions occur, discontinue DORYX MPC immediately and institute appropriate therapy.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="a607ab20-a63a-4007-a211-bafbf17b8d14"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Intracranial Hypertension</title>
                     <text>
                        <paragraph>Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracycline including DORYX MPC. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy.  Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH.  Avoid concomitant use of isotretinoin and DORYX MPC because isotretinoin is also known to cause pseudotumor cerebri. </paragraph>
                        <paragraph>Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists.  If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted.   Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="a35a978c-8405-4fb4-8e60-beae0481d74d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Skeletal Development</title>
                     <text>
                        <paragraph>All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.  [<content styleCode="italics">See <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="a2537ec8-7a75-431d-958b-12cbad4c3a62"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8	Antianabolic Action</title>
                     <text>
                        <paragraph>The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="df791d5e-b16a-49e5-9b7b-5f2c56e5b27b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9	Malaria</title>
                     <text>
                        <paragraph>Doxycycline offers substantial but not complete suppression of the asexual blood stages of <content styleCode="italics">Plasmodium</content> strains. </paragraph>
                        <paragraph>Doxycycline does not suppress <content styleCode="italics">P. falciparum's</content> sexual blood stage gametocytes. Subjects completing this prophylactic regimen may still transmit the infection to mosquitoes outside endemic areas.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="a7f2d941-c40f-4c74-8247-abb13898ec79"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10	Development of Drug-Resistant Bacteria</title>
                     <text>
                        <paragraph>Prescribing DORYX MPC in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.11">
                     <id root="09d06aa3-0168-4b3a-a13b-2978e301d1e0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11	Laboratory Monitoring for Long-Term Therapy</title>
                     <text>
                        <paragraph>In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal, and hepatic studies should be performed.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="a40b5af9-6849-4fc9-abfc-e7ec7849e210"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6	ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions have been identified during post-approval use of doxycycline. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>Due to oral doxycycline's virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines:</paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal:</content> Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, inflammatory lesions (with monilial overgrowth) in the anogenital region, and pancreatitis. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline-class. Most of these patients took medications immediately before going to bed [<content styleCode="italics">see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>
                     </content>].</paragraph>
                  <paragraph>
                     <content styleCode="italics">Skin:</content> Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, and fixed drug eruption have been reported. Photosensitivity is discussed above [<content styleCode="italics">see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>
                     </content>].</paragraph>
                  <paragraph>
                     <content styleCode="italics">Renal:</content> Rise in BUN has been reported and is apparently dose-related [<content styleCode="italics">see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>
                     </content>].</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hypersensitivity reactions:</content> Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Blood:</content> Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Intracranial Hypertension:</content> Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracycline [<content styleCode="italics">See <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>
                     </content>] </paragraph>
                  <paragraph>
                     <content styleCode="italics">Thyroid Gland Changes:</content> When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function are known to occur.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Psychiatric:</content> Depression, anxiety, suicidal ideation, insomnia, abnormal dreams, hallucination</paragraph>
               </text>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions observed in patients receiving tetracyclines include anorexia, nausea, vomiting, diarrhea, rash, photosensitivity, urticaria, and hemolytic anemia. (<linkHtml href="#S6">6</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="ab4e534f-4c4e-42a3-83af-e97967381ef5"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7	DRUG INTERACTIONS</title>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Avoid co-administration of tetracyclines with penicillin (<linkHtml href="#S7.2">7.2</linkHtml>)</item>
                           <item>Absorption of tetracyclines, including DORYX MPC is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations (<linkHtml href="#S7.3">7.3</linkHtml>)</item>
                           <item>Concurrent use of tetracyclines, including DORYX MPC  may render oral contraceptives less effective (<linkHtml href="#S7.4">7.4</linkHtml>)</item>
                           <item>Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline (<linkHtml href="#S7.5">7.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="49a1ccdc-5d2e-4e1e-a10c-e67264c2ee57"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Anticoagulant Drugs</title>
                     <text>
                        <paragraph>Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="da6d476d-2459-4049-8741-ed68711c46d5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Penicillin</title>
                     <text>
                        <paragraph>Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines, including DORYX MPC in conjunction with penicillin.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="3d2f3408-de33-46e2-a6a1-0b5b20c19eeb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3	Antacids and Iron Preparations</title>
                     <text>
                        <paragraph>Absorption of tetracyclines including DORYX MPC is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.4">
                     <id root="d9b67387-d9db-4e8f-b845-1d7850679a72"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4	Oral Contraceptives</title>
                     <text>
                        <paragraph>Concurrent use of tetracyclines, including DORYX MPC may render oral contraceptives less effective.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.5">
                     <id root="682fc2aa-cd66-4928-b148-66247e11c171"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5	Barbiturates and anti-epileptics</title>
                     <text>
                        <paragraph>Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.6">
                     <id root="fe9575c4-deab-48b5-8b8e-dc177ab83d0a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6	Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>False elevations of urinary catecholamines may occur due to interference with the fluorescence test.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="5e4c72b9-8809-49f9-9772-3087e8762608"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8	USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250301"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Tetracycline-class drugs can cause fetal harm when administered to a pregnant woman, but data for doxycycline are limited. (<linkHtml href="#S5.6">5.6</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>)</item>
                           <item>Tetracyclines are excreted in human milk; however, the extent of absorption of doxycycline in the breastfed infant is not known. DORYX MPC use during nursing should be avoided if possible. (<linkHtml href="#S8.2">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="33f3151c-504b-4bcb-8305-496266948430"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1	Pregnancy</title>
                     <effectiveTime value="20250301"/>
                     <component>
                        <section>
                           <id root="9e272291-ccc2-4a09-82d0-8919d50be3f9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no adequate studies on the use of doxycycline in pregnant women. The vast majority of reported experience with doxycycline during human pregnancy is short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women such as that proposed for the treatment of anthrax exposure. An expert review of published data on experiences with doxycycline use during pregnancy by TERIS - the Teratogen Information System - concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no risk.<sup>1</sup> In the U.S. general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively [<content styleCode="italics">see <linkHtml href="#DATA">Data</linkHtml>
                                 </content>]. </paragraph>
                           </text>
                           <effectiveTime value="20250301"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="14e0cb47-50d4-49c7-a3ad-a39d0192b4c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250301"/>
                           <component>
                              <section>
                                 <id root="a9570eda-02f7-48df-a5e2-4d45e6b73982"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Embryo/Fetal Risk</content>
                                    </paragraph>
                                    <paragraph>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity also has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus. [<content styleCode="italics">see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.6">5.6)</linkHtml>
                                       </content>].</paragraph>
                                 </text>
                                 <effectiveTime value="20250301"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="DATA">
                           <id root="b2c84918-afff-4b2a-87ed-581206352544"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250301"/>
                           <component>
                              <section>
                                 <id root="15c4016c-7735-4b21-bbd1-d62ae8f8e1ac"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. Sixty-three (0.19%) of the controls and 56 (0.30%) of the cases were treated with doxycycline. This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (i.e., in the second and third months of gestation), with the exception of a marginal relationship with neural tube defect based on only two-exposed cases.<sup>2</sup>
                                    </paragraph>
                                    <paragraph>A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester. All mothers reported their exposed infants were normal at 1 year of age.<sup>3</sup>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250301"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="8344429c-e88b-4dc2-8970-1b35d700c7b8"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2	Lactation</title>
                     <effectiveTime value="20250301"/>
                     <component>
                        <section>
                           <id root="06861476-80b7-45d3-81c2-ecdc44d0ecbb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Tetracyclines are excreted in human milk, however, the extent of absorption of tetracyclines including doxycycline, by the breastfed infant is not known. Short-term use by lactating women is not contraindicated. The effects of prolonged exposure to doxycycline on breast milk production and breast fed neonates, infants and children are unknown.<sup>4</sup> The developmental and health benefits of breast feeding should be considered along with the mother's clinical need for DORYX MPC and any potential adverse effects on the breast fed child from DORYX MPC or from the underlying maternal condition [<content styleCode="italics">see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.6">5.6)</linkHtml>
                                 </content>]. </paragraph>
                           </text>
                           <effectiveTime value="20250301"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="34f70d60-171d-4954-af64-b8a429b7c1be"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4	Pediatric  Use</title>
                     <text>
                        <paragraph>Because of the effects of drugs of the tetracycline-class on tooth development and growth, use DORYX MPC in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies [<content styleCode="italics">see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.6">5.6)</linkHtml> and <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#S2.4">2.4)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="8e588f38-d9ac-4fcc-b9fc-4a4796a97ca5"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5	Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of DORYX MPC did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. DORYX MPC Tablets each contain less than 10 mg of sodium.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="b4544e61-513f-4336-9836-ef59a5637945"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10	OVERDOSAGE</title>
               <text>
                  <paragraph>In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.</paragraph>
               </text>
               <effectiveTime value="20250301"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="bb21086d-53d5-48c7-99ba-95a26cb551ed"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11	DESCRIPTION</title>
               <text>
                  <paragraph>Doryx  MPC (doxycycline hyclate delayed-release tablets) for oral use, contain doxycycline hyclate, a tetracycline class drug  synthetically derived from oxytetracycline, in a delayed-release formulation consisting of pellets with a modified polymer enteric coat that has increased acid resistance.</paragraph>
                  <paragraph>The structural formula for doxycycline hyclate is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>with a molecular formula of C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>8</sub>, HCl, ½ C<sub>2</sub>H<sub>6</sub>O, ½ H<sub>2</sub>O and a molecular weight of 512.9.  The chemical name for doxycycline hyclate is [4S(4aR,5S,5aR,6R,12aS)]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-deoxonaphthacene-2-carboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate. Doxycycline hyclate is a yellow crystalline powder soluble in water and in solutions of alkali hydroxides and carbonates. Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.</paragraph>
                  <paragraph>Each tablet contains doxycycline 60 mg (equivalent to doxycycline hyclate 69.4 mg) or doxycycline 120 mg (equivalent to doxycycline hyclate 138.8 mg). Inactive ingredients in the tablet formulation are: lactose monohydrate; microcrystalline cellulose; sodium lauryl sulfate; sodium chloride; talc; anhydrous lactose; corn starch; crospovidone; magnesium stearate; cellulosic polymer coating.</paragraph>
                  <paragraph>Each DORYX MPC 60 mg Tablet contains 3.6 mg (0.157 mEq) of sodium.</paragraph>
                  <paragraph>Each DORYX MPC 120 mg Tablet contains 7.2 mg (0.313 mEq) of sodium.</paragraph>
               </text>
               <effectiveTime value="20250301"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="doryx-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="442ea5e3-23f8-49ed-a46b-9135e41896b2"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12	CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250301"/>
               <component>
                  <section ID="S12.1">
                     <id root="73e534ee-0bc6-402f-a180-700baeb08445"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	Mechanism of Action</title>
                     <text>
                        <paragraph>Doxycycline is a tetracycline-class antimicrobial drug [<content styleCode="italics">see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="513b10f4-47d5-4756-a747-4a303486b6e4"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3	Pharmacokinetics</title>
                     <effectiveTime value="20250301"/>
                     <component>
                        <section>
                           <id root="f898197b-2414-43c1-9861-922372ccfd2f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effect of Food</content>
                              </paragraph>
                              <paragraph>Following administration of a single dose of DORYX MPC under fasting conditions, the AUC<sub>inf</sub> and C<sub>max</sub> were 26.7 mcg-h/mL and 1.6 mcg/mL, respectively. The Tmax was 2.8 hours. In a single-dose study to evaluate the relative bioavailability in healthy adult subjects under fasted conditions, DORYX MPC 120 mg Tablets were found to be bioequivalent to Doryx 100 mg Tablets. When a single dose of DORYX MPC 120 mg Tablet was administered with a standardized high-fat high-calorie meal, (937kcal consisting of approximately 55% fat, 30% carbohydrate and 15% protein), the C<sub>max</sub> was approximately 30% lower, but there was no significant difference in the AUC<sub>inf</sub> compared to administration under fasting conditions <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250301"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="917a4917-bdec-42d8-8687-5cceabf6d301"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Doxycycline is virtually completely absorbed after oral administration.</paragraph>
                           </text>
                           <effectiveTime value="20250301"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="41f42a32-a7bd-4cc7-9791-1a12b6e2c08b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>Tetracyclines are concentrated in bile by the liver and excreted in the urine and feces at high concentrations and in a biologically active form. Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with a creatinine clearance of about 75 mL/min. This percentage may fall as low as 1-5%/72 hours in individuals with a creatinine clearance below 10 mL/min.</paragraph>
                           </text>
                           <effectiveTime value="20250301"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="5e03098d-7737-4a79-8c78-e3502aa859f8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250301"/>
                           <component>
                              <section>
                                 <id root="9649b8a4-cf52-4c7f-9f14-cc96b150ed3f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Studies have shown no significant difference in the serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely impaired renal function. Hemodialysis does not alter the serum half-life.</paragraph>
                                 </text>
                                 <effectiveTime value="20250301"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="33517b00-d96c-48b4-98b8-a8b2a2797f66"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>Population pharmacokinetic analysis of sparse concentration-time data of doxycycline. following standard of care intravenous and oral dosing in 44 children (2-18 years of age) showed that allometrically-scaled clearance of doxycycline in children ≥2 to ≤8 years of age (median [range] 3.58 [2.27-10.82] L/h/70 kg, N=11) did not differ significantly from children &gt;8 to 18 years of age (3.27 [1.11-8.12] L/h/70 kg, N=33). For pediatric patients weighing ≤45 kg, body weight normalized doxycycline CL in those ≥2 to ≤8 years of age (median [range] 0.071 [0.041-0.202] L/kg/h, N=l0) did not differ significantly from those &gt;8 to 18 years of age (0.081 [0.035-0.126] L/kg/h, N=8). In pediatric patients weighing &gt;45 kg no clinically significant differences in body weight normalized doxycycline CL were observed between those ≥2 to ≤8 years (0.050 L/kg/h, N=l) and those &gt;8 years of age (0.044 [0.014-0. 121] L/kg/h, N=25). No clinically significant difference in CL differences between oral and IV were observed in the small cohort of pediatric patients who received the oral (N=l9) or IV (N=21) formulation alone.</paragraph>
                                 </text>
                                 <effectiveTime value="20250301"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="05867bf3-3d00-4a37-a9fe-75b5c8409fe2"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4	Microbiology</title>
                     <effectiveTime value="20250301"/>
                     <component>
                        <section>
                           <id root="323a40aa-4035-4b5d-b616-11c9b255d95a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Action</content>
                              </paragraph>
                              <paragraph>Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. </paragraph>
                           </text>
                           <effectiveTime value="20250301"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="87655f18-0009-40ed-b674-0868d1fc69b2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Resistance</content>
                              </paragraph>
                              <paragraph>Cross-resistance between tetracyclines is common.</paragraph>
                           </text>
                           <effectiveTime value="20250301"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f2da03e1-f9dc-4d42-84ec-28d140f41595"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antimicrobial Activity</content>
                              </paragraph>
                              <paragraph>Doxycycline has been shown to be active against most isolates of the following bacteria, both <content styleCode="italics">in vitro</content> and in clinical infections [see <content styleCode="italics">
                                    <linkHtml href="#S1">Indications and Usage (1)</linkHtml>
                                 </content>].</paragraph>
                           </text>
                           <effectiveTime value="20250301"/>
                           <component>
                              <section>
                                 <id root="6cdb907c-9369-43b3-8bca-7e850c061a9c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Gram-negative Bacteria</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Acinetobacter</content> species<br/>
                                       <content styleCode="italics">Bartonella bacilliformis<br/>Brucella</content> species<br/>
                                       <content styleCode="italics">Campylobacter fetus<br/>Enterobacter aerogenes<br/>Escherichia coli <br/>Francisella tularensis<br/>Haemophilus ducreyi<br/>Haemophilus influenzae<br/>Klebsiella granulomatis <br/>Klebsiella</content> species<br/>
                                       <content styleCode="italics">Neisseria gonorrhoeae<br/>Shigella</content> species<br/>
                                       <content styleCode="italics">Vibrio cholerae<br/>Yersinia pestis</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Gram-positive Bacteria</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Bacillus anthracis<br/>Listeria monocytogenes<br/>Streptococcus pneumoniae</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Anaerobic Bacteria</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Clostridium</content> species<br/>
                                       <content styleCode="italics">Fusobacterium fusiforme<br/>Propionibacterium acnes</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Other Bacteria</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Norcardiae</content> and other aerobic <content styleCode="italics">Actinomyces</content> species<br/>
                                       <content styleCode="italics">Borrelia recurrentis<br/>Chlamydophila psittaci<br/>Chlamydia trachomatis<br/>Mycoplasma pneumonia</content>
                                       <br/>Rickettsiae<br/>
                                       <content styleCode="italics">Treponema pallidum<br/>Treponema pallidum</content> subspecies <content styleCode="italics">pertenue<br/>Ureaplasma urealyticum</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Parasites</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Balantidium coli<br/>Entamoeba</content> species<br/>
                                       <content styleCode="italics">Plasmodium falciparum</content>
                                       <footnote>Doxycycline has been found to be active against the asexual erythrocytic forms of <content styleCode="italics">Plasmodium falciparum</content> but not against the gametocytes of <content styleCode="italics">P. falciparum.</content> The precise mechanism of action of the drug is not known. </footnote>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250301"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b48a7b31-159a-4ece-9d49-6903477f4766"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Susceptibility Testing</content>
                              </paragraph>
                              <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized  by FDA for this drug, please see: https://www.fda.gov/STIC.</paragraph>
                           </text>
                           <effectiveTime value="20250301"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="526f770f-4b84-42dd-a241-894255d522b2"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13	NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250301"/>
               <component>
                  <section ID="S13.1">
                     <id root="a4ae5ce6-c192-46b7-ba7a-8710db428f4e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term studies in animals to evaluate carcinogenic potential of doxycycline have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with the related antibiotics, oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors). Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in <content styleCode="italics">in vitro</content> mammalian cell assays have been reported for related antibacterials (tetracycline, oxytetracycline).</paragraph>
                        <paragraph>Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had no apparent effect on the fertility of female rats. Effect on male fertility has not been studied.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="1d01a012-3abd-41bf-883b-b1e3aa419ebc"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2	Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Hyperpigmentation of the thyroid has been produced by members of the tetracycline-class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO<sub>4</sub>, and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO<sub>4</sub>, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.</paragraph>
                        <paragraph>Minocycline, tetracycline PO<sub>4</sub>, methacycline, doxycycline, tetracycline base, oxytetracycline HCl, and tetracycline HCl, were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large goiter with high radioiodine uptake in rats fed a relatively high iodine diet.</paragraph>
                        <paragraph>Treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the following: in rats and dogs (minocycline); in chickens (chlortetracycline); and in rats and mice (oxytetracycline). Adrenal gland hyperplasia has been observed in goats and rats treated with oxytetracycline. </paragraph>
                        <paragraph>Results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues.</paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S15">
               <id root="7a800629-8882-4f45-808e-36edaed2aa32"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15	REFERENCES </title>
               <text>
                  <list listType="ordered" styleCode="Arabic">
                     <item>Friedman JM, Polifka JE.  <content styleCode="italics">Teratogenic Effects of Drugs.  A Resource for Clinicians (TERIS)</content>.  Baltimore, MD: The Johns Hopkins University Press: 2000: 149-195. The TERIS (Teratogen Information System) is available at: http://www.micromedexsolutions.com/ (cited: 2016 Jan).</item>
                     <item>Cziezel AE and Rockenbauer M. Teratogenic study of doxycycline. <content styleCode="italics">Obstet Gynecol</content> 1997; 89: 524-528. </item>
                     <item>Horne HW Jr. and Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: a prospective study. <content styleCode="italics">Int J Fertil</content> 1980; 25: 315-317. </item>
                     <item>Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); [Last Revision Date 2015 March 10; cited 2016 Jan]. Doxycycline; LactMed Record Number: 100; [about 3 screens]. Available from: http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm</item>
                  </list>
               </text>
               <effectiveTime value="20250301"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="8e38e80c-3771-4b85-9e4a-308cd71d76be"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16	HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>DORYX MPC (doxycycline hyclate delayed-release tablets), 60 mg are white, oval tablets containing yellow pellets and debossed with "D6" on one face and plain on the other. Each tablet contains doxycycline 60 mg (equivalent to doxycycline hyclate 69.4 mg).</paragraph>
                  <paragraph>The 60 mg tablet is supplied in bottles of 60 tablets (NDC 51862-560-60) and 120 tablets (NDC 51862-560-12).</paragraph>
               </text>
               <effectiveTime value="20250301"/>
               <component>
                  <section>
                     <id root="81b67ebc-20e6-4dcc-a04a-5ebb2c60789f"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at 25° C (77° F); excursions permitted to 15°C to 30° C (59°F to 86° F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container (USP). </paragraph>
                     </text>
                     <effectiveTime value="20250301"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="9f5b5818-c9c2-46a3-b006-39eaa0014d5b"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17	PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise patients taking DORYX MPC for malaria prophylaxis:</paragraph>
                  <list>
                     <item>that no present-day antimalarial agent, including doxycycline, guarantees protection against malaria.</item>
                     <item>to avoid being bitten by mosquitoes by using personal protective measures that help avoid contact with mosquitoes, especially from dusk to dawn (for example, staying in well-screened areas, using mosquito nets, covering the body with clothing, and using an effective insect repellent).</item>
                     <item>that doxycycline prophylaxis: <list listType="unordered">
                           <item>
                              <caption>–</caption>should begin 1 to 2 days before travel to the malarious area,</item>
                           <item>
                              <caption>–</caption>should be continued daily while in the malarious area and after leaving the malarious area,</item>
                           <item>
                              <caption>–</caption>should be continued for 4 further weeks to avoid development of malaria after returning from an endemic area,</item>
                           <item>
                              <caption>–</caption>should not exceed 4 months.</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>Advise all patients taking DORYX MPC:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if phototoxicity (for example, skin eruptions, etc.) occurs. Sunscreen or sunblock should be considered [<content styleCode="italics">see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>
                        </content>]</item>
                     <item>to drink fluids liberally along with DORYX MPC to reduce the risk of esophageal irritation and ulceration [<content styleCode="italics">see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>
                        </content>]</item>
                     <item>that the absorption of tetracyclines is reduced when taken with foods, especially those that contain calcium.  [<content styleCode="italics">see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>
                        </content>]</item>
                     <item>that if gastric irritation occurs, DORYX MPC may be given with food or milk [<content styleCode="italics">see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>
                        </content>] </item>
                     <item>that the absorption of tetracyclines is reduced when taken with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations [<content styleCode="italics">see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>
                        </content>].</item>
                     <item>that the use of doxycycline might increase the incidence of vaginal candidiasis.</item>
                  </list>
                  <paragraph>Advise patients that diarrhea is a common problem caused by antibacterial drugs which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of antibacterial. If this occurs, patients should contact their physician as soon as possible.</paragraph>
                  <paragraph>Patients should be counseled that antibacterial drugs including DORYX MPC should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When DORYX MPC is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by DORYX MPC or other antibacterial drugs in the future.</paragraph>
               </text>
               <effectiveTime value="20250301"/>
            </section>
         </component>
         <component>
            <section>
               <id root="47a81180-94d3-405c-8bac-f4ef3febfd40"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Mayne Pharma</content>
                     <br/>Raleigh, NC 27609</paragraph>
                  <paragraph>61596</paragraph>
               </text>
               <effectiveTime value="20250301"/>
            </section>
         </component>
         <component>
            <section>
               <id root="4277bc80-0e01-4b33-9820-1cd020110c87"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 60 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 51862-560-12</paragraph>
                  <paragraph>Doryx<sup>®</sup> MPC<br/> (Doxycycline Hyclate<br/>Delayed-Release Tablets)</paragraph>
                  <paragraph>60 mg</paragraph>
                  <paragraph>Do not chew or crush tablets.</paragraph>
                  <paragraph>Rx Only<br/>120 Tablets</paragraph>
                  <paragraph>mayne pharma</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250301"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 60 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="doryx-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="3d1a8773-150c-4334-8e3f-5fa808c62be0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 120 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 51862-559-30</paragraph>
                  <paragraph>Doryx<sup>®</sup> MPC<br/> (Doxycycline Hyclate<br/>Delayed-Release Tablets)</paragraph>
                  <paragraph>120 mg</paragraph>
                  <paragraph>Do not chew or crush tablets.</paragraph>
                  <paragraph>Rx Only<br/>30 Tablets</paragraph>
                  <paragraph>mayne pharma</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250301"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 120 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="doryx-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>